Literature DB >> 1532669

Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.

Z G Zhang1, A Harstrick, Y M Rustum.   

Abstract

The biochemical modulation of 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) by leucovorin (LV) has resulted in a significant improvement of the antitumor activity in a variety of malignancies. Although this combination is frequently used, the optimal dose and schedule of LV remains to be determined. In vitro studies with human colon carcinoma (HCT-8) and renal carcinoma (SE) cells show that the increase of intracellular folate pools by LV is dose and time dependent and varies significantly between cell lines. While HCT-8 cells showed optimal modulation of FdUrd cytotoxicity with 1 mumol/L [6S]LV for 5 hours, SE cells required 10 mumol/L [6S]LV for 5 days. Clinical data indicate that low doses of [6R,S]LV (20 mg/m2) might be equivalent to higher doses (200 to 500 mg/m2) when 5-FU is given on 5 consecutive days, whereas doses of 200 mg/m2 might be necessary when 5-FU chemotherapy is given once weekly. Unless biochemical assays to assess a patient's individual needs of LV become available, the use of higher (200 to 500 mg/m2) doses might offer the best chance to effectively modulate 5-FU clinically.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532669

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

1.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  Systemic treatment of colorectal cancer.

Authors:  Brian M Wolpin; Robert J Mayer
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 4.  Metastatic colorectal cancer-past, progress and future.

Authors:  Kathryn Field; Lara Lipton
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

5.  Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen.

Authors:  P J Creaven; Y M Rustum; N J Petrelli; N J Meropol; D Raghavan; M Rodriguez-Bigas; E G Levine; C Frank; S Udvary-Nagy; A Proefrock
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.

Authors:  D M Voeller; C J Allegra
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.